Becton, Dickinson and Company (BD) has secured 510(k) clearance from the US Food and Drug Administration (FDA) and CE marking under the European Union’s In Vitro Diagnostic Regulation (IVDR) for its bacterial panels for use on the BD COR System.
Employing polymerase chain reaction (PCR) techniques, the Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) panels test for numerous gastrointestinal (GI) bacterial pathogens using a single stool swab.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The BD EBP detects a broad spectrum of enteric bacteria, including Shigella species / Enteroinvasive Escherichia coli (EIEC), Shiga toxin-producing Escherichia coli (STEC), and various Salmonella and Campylobacter species.
The bacterial-only EBP plus molecular panel identifies Enterotoxigenic Escherichia coli (ETEC) and the associated heat-labile enterotoxin (LT) and heat-stable enterotoxin (ST) genes.
It also tests for Yersinia enterocolitica, Vibrio species, and Plesiomonas shigelloides.
According to BD, these capabilities support quick detection for diarrhoeal illness treatment and could help minimise needless antibiotic use.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBD Diagnostic Solutions worldwide president Nikos Pavlidis said: “Traditional GI tests can take days, and when patients are experiencing symptoms such as diarrhoea or vomiting, delays can be potentially life-threatening.
“With EBP and EBP plus, clinicians choose the panel that best fits their clinical needs to quickly identify specific pathogens from a single swab, streamlining lab workflows and enabling targeted treatment to help protect vulnerable patients.”
The BD COR System is said to automate molecular diagnostics in laboratories. It is capable of processing about 1,650 tests with up to 1,000 results produced within 24 hours.
Features include barcode-based sample tracking, remote management capabilities, up to seven hours of unattended operation, a loading time under 15 minutes, and the use of room-temperature reagents that do not need to be reconstituted.
The company also offers syndromic panels on the BD MAX platform to detect extended bacterial pathogens, as well as viral and parasitic causes of infectious diarrhoea.
In August 2025, the company announced an investment of more than $35m to expand the manufacturing of BD PosiFlush prefilled flush syringes at its facility in Columbus, US.
